[go: up one dir, main page]

JP2007519662A - タンパク質キナーゼ依存性疾患の処置に使用するためのピラゾロ[1,5−a]ピリミジン−7−イル−アミン誘導体 - Google Patents

タンパク質キナーゼ依存性疾患の処置に使用するためのピラゾロ[1,5−a]ピリミジン−7−イル−アミン誘導体 Download PDF

Info

Publication number
JP2007519662A
JP2007519662A JP2006550056A JP2006550056A JP2007519662A JP 2007519662 A JP2007519662 A JP 2007519662A JP 2006550056 A JP2006550056 A JP 2006550056A JP 2006550056 A JP2006550056 A JP 2006550056A JP 2007519662 A JP2007519662 A JP 2007519662A
Authority
JP
Japan
Prior art keywords
phenyl
pyrazolo
methyl
pyrimidin
ylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006550056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519662A5 (zh
Inventor
グイド・ボルト
アンドレアス・フレールスハイマー
パスカル・フュレ
パトリツィア・イムバッハ
圭一 舛屋
ヨーゼフ・シェープファー
ゲオルク・マルティニー−バロン
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007519662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2007519662A publication Critical patent/JP2007519662A/ja
Publication of JP2007519662A5 publication Critical patent/JP2007519662A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006550056A 2004-01-22 2005-01-21 タンパク質キナーゼ依存性疾患の処置に使用するためのピラゾロ[1,5−a]ピリミジン−7−イル−アミン誘導体 Pending JP2007519662A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53822004P 2004-01-22 2004-01-22
PCT/EP2005/000602 WO2005070431A1 (en) 2004-01-22 2005-01-21 Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases

Publications (2)

Publication Number Publication Date
JP2007519662A true JP2007519662A (ja) 2007-07-19
JP2007519662A5 JP2007519662A5 (zh) 2008-03-06

Family

ID=34807167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550056A Pending JP2007519662A (ja) 2004-01-22 2005-01-21 タンパク質キナーゼ依存性疾患の処置に使用するためのピラゾロ[1,5−a]ピリミジン−7−イル−アミン誘導体

Country Status (17)

Country Link
EP (1) EP1708710A1 (zh)
JP (1) JP2007519662A (zh)
KR (1) KR20070009546A (zh)
CN (1) CN1909908A (zh)
AR (1) AR049769A1 (zh)
AU (1) AU2005205915B2 (zh)
BR (1) BRPI0507071A (zh)
CA (1) CA2552885A1 (zh)
EC (1) ECSP066718A (zh)
IL (1) IL176737A0 (zh)
MA (1) MA28400B1 (zh)
NO (1) NO20063758L (zh)
PE (1) PE20051089A1 (zh)
RU (1) RU2006130003A (zh)
TN (1) TNSN06226A1 (zh)
TW (1) TW200528103A (zh)
WO (1) WO2005070431A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512079A (ja) * 2018-01-29 2021-05-13 メルク パテント ゲーエムベーハー Gcn2阻害剤およびその使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CA2627623C (en) * 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
JP5052518B2 (ja) 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
PT1973545E (pt) 2005-12-23 2013-02-11 Ariad Pharma Inc Compostos de heteroarilo bicíclicos
BRPI0708693A2 (pt) * 2006-03-08 2011-06-14 Novartis Ag uso de derivados de pirazol[1,5,a]pirimidin-7-il amina no tratamento de distérbios neurolàgicos
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
GB0606805D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic compounds
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
JP2010504927A (ja) * 2006-09-28 2010-02-18 ノバルティス アーゲー ピラゾロ[1,5−a]ピリミジン誘導体およびそれらの治療的使用
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
EP1918291A1 (en) * 2006-10-30 2008-05-07 Novartis AG 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
WO2008153870A1 (en) * 2007-06-07 2008-12-18 Schering Corporation Synthesis of substituted-3-aminopyrazoles
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Erk阻害剤である新規化合物
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
DK2918588T3 (en) 2010-05-20 2017-08-28 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
CN104803997A (zh) * 2010-08-09 2015-07-29 株式会社创药分子设计 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂
WO2012023143A1 (en) 2010-08-19 2012-02-23 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US20150038500A1 (en) * 2011-11-25 2015-02-05 Catholic University Industry-Academic Cooperation Foundation Pharmaceutical composition for preventing and treating ophthalmic disorders
CN105906630B (zh) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN106588893A (zh) * 2016-12-01 2017-04-26 北京万全德众医药生物技术有限公司 维拉佐酮双氧化物的制备
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
BR112020015396A2 (pt) 2018-01-29 2020-12-08 Merck Patent Gmbh Inididores de gcn2 e usos dos mesmos
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
CN109836428A (zh) * 2019-02-27 2019-06-04 华东师范大学 具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途
US20210008173A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
CN114728167B (zh) 2019-11-25 2024-03-19 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
WO2023154282A1 (en) * 2022-02-08 2023-08-17 Theras, Inc. Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
CN114751910B (zh) * 2022-05-17 2023-02-24 重庆文理学院 一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843974A (ja) * 1981-08-01 1983-03-14 バスフ・アクチエンゲゼルシヤフト 7―アミノ―アゾロ[1,5―a]ピリミジン及び該化合物を含有する農園芸用殺菌剤
EP0591528A1 (en) * 1991-04-22 1994-04-13 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
JPH08310951A (ja) * 1994-06-21 1996-11-26 Otsuka Pharmaceut Factory Inc 鎮痛剤
JP2006500391A (ja) * 2002-09-04 2006-01-05 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006502161A (ja) * 2002-09-04 2006-01-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69523864T2 (de) * 1994-06-21 2002-06-13 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a] PYRIMIDIN-DERIVATE
WO1998010590A1 (fr) * 1996-09-02 1998-03-12 Sony Corporation Dispositif et procede de transmission d'un signal video

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843974A (ja) * 1981-08-01 1983-03-14 バスフ・アクチエンゲゼルシヤフト 7―アミノ―アゾロ[1,5―a]ピリミジン及び該化合物を含有する農園芸用殺菌剤
EP0591528A1 (en) * 1991-04-22 1994-04-13 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
JPH08310951A (ja) * 1994-06-21 1996-11-26 Otsuka Pharmaceut Factory Inc 鎮痛剤
JP2006500391A (ja) * 2002-09-04 2006-01-05 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006502161A (ja) * 2002-09-04 2006-01-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512079A (ja) * 2018-01-29 2021-05-13 メルク パテント ゲーエムベーハー Gcn2阻害剤およびその使用
JP7229257B2 (ja) 2018-01-29 2023-02-28 メルク パテント ゲーエムベーハー Gcn2阻害剤およびその使用
JP2023057115A (ja) * 2018-01-29 2023-04-20 メルク パテント ゲーエムベーハー Gcn2阻害剤およびその使用
JP7703586B2 (ja) 2018-01-29 2025-07-07 メルク パテント ゲーエムベーハー Gcn2阻害剤およびその使用

Also Published As

Publication number Publication date
NO20063758L (no) 2006-10-23
AU2005205915A1 (en) 2005-08-04
CN1909908A (zh) 2007-02-07
ECSP066718A (es) 2006-10-31
RU2006130003A (ru) 2008-04-10
EP1708710A1 (en) 2006-10-11
WO2005070431A1 (en) 2005-08-04
IL176737A0 (en) 2006-10-31
TNSN06226A1 (en) 2007-12-03
AR049769A1 (es) 2006-09-06
MA28400B1 (fr) 2007-01-02
AU2005205915B2 (en) 2009-05-21
BRPI0507071A (pt) 2007-06-19
PE20051089A1 (es) 2006-01-25
KR20070009546A (ko) 2007-01-18
TW200528103A (en) 2005-09-01
CA2552885A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
JP2007519662A (ja) タンパク質キナーゼ依存性疾患の処置に使用するためのピラゾロ[1,5−a]ピリミジン−7−イル−アミン誘導体
US20090099167A1 (en) Organic compounds
US20080234284A1 (en) Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors
JP2010508324A (ja) プロテインキナーゼモジュレーターとしての3−アミノカルボニル置換縮合ピラゾロ誘導体
JP2009517419A (ja) EphBおよびVEGFR2キナーゼ阻害剤としての3−(置換アミノ)−ピラゾロ[3,4−d]ピリミジン
JP2008519790A (ja) キナーゼ阻害剤としての1,4−置換ピラゾロピリミジン
JP2009518340A (ja) EphBおよびVEGFR2キナーゼ阻害剤としてのピラゾロ[1,5−a]ピリジン−3−カルボン酸
EP2004653B1 (en) 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors
JP2008509187A (ja) キナーゼ阻害剤としてのトリフルオロメチル置換ベンズアミド
JP2010504933A (ja) Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
JP2008526804A (ja) キナーゼ阻害剤としてのジ置換ウレア
JP2012131795A (ja) 増殖性疾患の処置に有用なピロロピリミジン誘導体
JP2009532400A (ja) キナーゼ阻害剤としての3−非置換N−(アリール−もしくはヘテロアリール)−ピラゾロ[1,5−a]ピリミジン
JP2010508325A (ja) プロテインキナーゼの阻害剤として有用な3−アミノ−ピラゾール−4−カルボキサミド誘導体
MXPA06008303A (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802